All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was pleased to speak with Jorge Cortes, Augusta University, Augusta, US. We asked, How might long-term follow-up data regarding olutasidenib impact treatment strategies in patients with IDH1-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML)?
How might olutasidenib long-term data impact treatment strategies in patients with IDH1-mu R/R AML?
In December 2022, olutasidenib was granted U.S. Food and Drug Administration (FDA) approval for the treatment of patients with IDH1-mutated R/R AML. Here, Cortes discusses the final 5-year efficacy and safety findings from the pivotal cohort of the phase II trial (NCT02719574) of olutasidenib in patients with IDH1-mutated R/R AML. Cortes highlights the high complete remission (CR)/CR with partial hematological recovery rate (35%), overall response rate (48%) and durable remission rates, as well as the prolonged survival and minimal toxicity of olutasidenib in patients with IDH1-mutated R/R AML including in patients who are R/R to prior venetoclax therapy. He mentions that olutasidenib is a promising treatment option for patients with R/R AML with IDH1 mutations; however, its comparison with other treatments, such as ivosidenib—which is also highly effective and commercially available—remains uncertain without a randomized trial.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox